For years, the American Society of Clinical Oncologys annual meeting has served as the main forum for advances in cancer immunotherapies like Merck & Co.s Keytruda and Bristol Myers Squibbs Opdivo.
While new data continue to emerge for those drugs and their competitors, this years conference was headlined by dramatic data for another type of cancer medicine from AstraZeneca and Daiichi Sankyo, which put pressure on rival Gilead. And with CAR-T therapies now established, attention has shifted to other emerging approaches for training the immune system to attack tumors.
Read on for updates on Gilead, bispecific antibodies for blood cancer and gamma delta cell therapy.
ASCO is an important conference for any biotech developing a cancer drug. But this years meeting was particularly so for Gilead, which has spent a decade and billions of dollars trying to build its oncology business. Analysts and investors were eagerly awaiting the details of a key study of the breast cancer drug Trodelvy, for which it paid $21 billion to acquire last year. Updates were also expected for magrolimab, another cancer medicine Gilead recently bought in a large deal.
The drugs either underwhelmed or were upstaged by others, however. Trodelvy led to a 1.5-month improvement over chemotherapy on a measure of tumor progression in a late-stage study of patients with a common form of metastatic breast cancer. The result fell short of the 2-month target doctors surveyed by analyst firm RBC Capital Markets felt would warrant meaningful use, according to a research note.
Trodelvy was also overshadowed by AstraZeneca and Daiichi Sankyos rival breast cancer drug, Enhertu, whose data in so-called HER2 low tumors were so striking they received a standing ovation at the meeting.
All the enthusiasm for Trodelvy has evaporated after those results, wrote Baird analyst Brian Skorney in a note on Sunday, adding that Enhertus likely approval in HER2 low breast cancer could limit Trodelvys revenue potential.
Analysts were similarly unimpressed by the latest data for magrolimab, a blood cancer drug that was slowed by safety concerns this year. Initial data showed a response rate of 50% for a combination of magrolimab and the chemotherapy azacitidine in an early-stage trial in myelodysplastic syndrome. That rate has fallen to 33% with additional data, barely surpassing whats been observed in tests of chemotherapy alone, Skorney wrote.
Complete response rates slipped in a Phase 1 acute myeloid leukemia study as well. The updates show Gileads drug has sufficient activity, though its perhaps not the home run it was initially hoped to be, wrote RBC analyst Brian Abrahams in a note to clients.
Gilead will likely need to show more before investors view the cancer portfolio as a major growth driver, Abrahams added. Shares ticked down 2% in early Monday trading.
The biotech did get a reprieve on Friday, however, announcing that regulators had lifted their last remaining hold on studies of magrolimab in lymphoma and multiple myeloma.
Cell therapy has become a powerful new treatment option for blood cancers like lymphoma and multiple myeloma. Approved drugs from Gilead, Bristol Myers Squibb, Novartis and Johnson & Johnson use souped-up immune cells genetically modified and infused back into patients to attack cancers.
But the approach, while potent, involves a painstaking manufacturing process that requires physicians to carefully time treatment. In multiple myeloma, Bristol Myers and J&J have struggled to keep up with demand, Stat News has reported, further complicating cell therapy's use.
While drugmakers expect to overcome those hurdles with time, they are busy advancing other ways to redirect immune cells to target cancer. One alternative uses an antibody to latch onto protein flags found on the surface of immune cells and their cancerous targets, bringing them into tumor-killing contact.
These so-called bispecific antibodies have already shown promise in some of the same blood cancers addressed by CAR-T cell therapies. At ASCO, Roche and J&J revealed updated clinical trial data supporting their respective medicines for lymphoma and multiple myeloma. AbbVie and partner Genmab, meanwhile, will present data on their lymphoma bispecific antibody at the European Hematology Association's meeting next weekend.
Scott Gottlieb, formerly Food and Drug Administration commissioner and currently a member of Pfizers board, pointed to bispecific antibody data as some of the most exciting to come out of ASCO this year.
"That data looks very promising," he said on CNBCs Squawkbox program Monday, noting the therapies from Roche and partners AbbVie and Genmab specifically.
Specifically, Roche's data showed treatment led to responses in half of patients with relapsed or refractory diffuse large B-cell lymphoma who were treated in the study. Nearly 40% went into remission.
Notably, about a third of the 154 participants had previously received CAR-T therapies, which have recently been approved in the U.S. for earlier use in treating advanced lymphoma.
"We still need longer follow-up for the bispecific antibodies," said Kerry Savage, a medical oncologist at The University of British Columbia, who discussed Roche's abstract at ASCO on Friday. "We don't know the curative potential yet, but it's certainly encouraging so far."
AbbVie and Genmab's results, which will be presented on Saturday at EHA, showed a slightly higher overall response rate of 63% and a similar remission rate of 39% among adults with several variations of relapsed or refractory large B-cell lymphoma.
J&J, meanwhile, brought updated data to ASCO for its multiple myeloma bispecific teclistamab, which were also published in The New England Journal of Medicine. The data showed treatment could beat back cancer and, in about 40% of patients, lead to remission.
"The high rate of deep and durable responses in this population indicates the potential for teclistamab to provide substantial clinical benefit to a broader population of patients," researchers wrote in NEJM.
The search for more convenient alternatives to personalized cell therapies has led to other off-the-shelf strategies besides bispecific antibodies. One emerging approach involves gamma delta T cells, rare white blood cells that can recognize a range of targets.
Adicet Bio, In8Bio, Immatics, among others, are developing treatments and multiple large companies have shown interest in their work. Bristol Myers Squibb just last week expanded an existing deal with Immatics, while Takeda and Johnson & Johnson have recently made investments, too.
Adicets program, a potential treatment for non-Hodgkins lymphoma, is the most advanced of the group, making its trial results an important proof point for the field.
Prior to the meeting, Adicet said four of six treated patients with a low or medium dose went into remission, with two of the three patients treated still cancer free after three months. Importantly, there were no serious immune or neurological side effects reported.
At ASCO, Adicet disclosed results from two additional patients as well as longer follow-up from others. While early, the findings are in the range with CAR-T therapy. As of May 31, six of eight patients including two at the highest tested dose had responded to treatment. All six initially went into remission.
Notably, these were heavily pretreated patients, three of whom whose disease had progressed after CAR-T. Adicet hasnt reported any cases of severe cytokine release syndrome, a common side effect of CAR-T.
Yet the treatments durability remains in question. Though four of the complete responses are ongoing, only one has lasted longer than six months. One patient previously in remission died from COVID-19, while another relapsed.
Adicet plans to pick a dose to advance into further testing. The company amended its trial to include a higher dose as well as potentially evaluate a multiple-dose regimen, a strategy other off-the-shelf cell therapy developers are testing as well.
Go here to see the original:
ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy - BioPharma Dive
- Cell-Based Regenerative Medicine Market Size to Witness Rapid Growth at a CAGR of 15% by 2032 | insightSLICE - EIN News - May 9th, 2023
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 21st, 2023
- Cell culture - Wikipedia - December 18th, 2022
- The Legacy of Henrietta Lacks - Hopkins Medicine - December 10th, 2022
- HOME | Stem cell & Cancer - October 4th, 2022
- CAR T Cell Therapy Offers a New Hope in the Treatment of Severe and Refractory Systemic Lupus Erythematosus - Rheumatology Network - October 4th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 4th, 2022
- Outlook on the Automated Cell Counters Global Market to 2028 - Use of Cell Counters in Personalized Medicine Presents Opportunities -... - October 4th, 2022
- Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Marketscreener.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - BioPharm International - October 4th, 2022
- Breakthrough in production of cancer-treating drug - Stanford University News - October 4th, 2022
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 4th, 2022
- Mary Munson elected fellow of the American Society for Cell Biology - UMass Medical School - October 4th, 2022
- 5 FDA decisions to watch in the fourth quarter - BioPharma Dive - October 4th, 2022
- bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease -... - October 4th, 2022
- Laser Focus World highlights UC research that uses light to restore cell function - University of Cincinnati - October 4th, 2022
- The Institute of Regenerative Medicine | Non-Surgical, Cell-Based ... - September 25th, 2022
- CAR T-Cell Therapy Shows Promise in Treating Lupus - Healthline - September 25th, 2022
- ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit - El Paso Inc. - September 25th, 2022
- Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit - GlobeNewswire - September 25th, 2022
- Alzheimer's disease risk linked to newly discovered protein mutation - Medical News Today - September 25th, 2022
- Biological Links Identified Between an Aggressive Breast Cancer Type and African Ancestry - Weill Cornell Medicine Newsroom - September 25th, 2022
- The Use of Nanorobotics in the Treatment Therapy of Cancer and Its Future Aspects: A Review - Cureus - September 25th, 2022
- UW Health, UW-Madison School of Medicine and Public Health: Innovative clinical trial targets recurrent BK infection in kidney transplant recipients -... - September 25th, 2022
- Shutting down backup genes leads to cancer remission in mice - University of Michigan News - September 25th, 2022
- Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges... - September 25th, 2022
- FDA's ODAC Votes That Benefits Do Not Outweigh Risks for Poziotinib in HER Exon 20 Ins+ NSCLC - Targeted Oncology - September 25th, 2022
- Courageous Lanarkshire teen who survived leukaemia thanks to a clinical trial pursues nursing dream - Daily Record - September 25th, 2022
- Discovery Reveals How the Immune System Tolerates Friendly Gut Bacteria - Weill Cornell Medicine Newsroom - September 8th, 2022
- Study: New Factors Are Associated With Increased PFS from BCMA-Targeted T-Cell Therapy - Pharmacy Times - September 8th, 2022
- Study Uncovers Possible Path for Improving T Cell Therapies - University of Arizona - September 8th, 2022
- Trodelvy Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study - Gilead Sciences - September 8th, 2022
- Manipulating Astrocytes in Tumor Environment Effective Against Glioblastoma - Inside Precision Medicine - September 8th, 2022
- Jane Fonda Diagnosed with Non-Hodgkin's Lymphoma: What to Know - Healthline - September 8th, 2022
- Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC - AJMC.com Managed Markets Network - August 30th, 2022
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022
- The Role of Eosinophils as a Biomarker to Inform Treatment Decisions for Patients With COPD - Consultant360 - August 30th, 2022
- Scientists Discover Surprise Anticancer Properties of Common Lab Molecule | Newsroom - UNC Health and UNC School of Medicine - August 30th, 2022
- Overall survival is similar for patients receiving CT-based or minimal follow-up after surgical resection of non-small-cell lung cancer - 2 Minute... - August 30th, 2022
- NSF Grant to Aid OSU Researchers Developing Treatment for Canine Cancer - The Corvallis Advocate - August 30th, 2022
- Researchers Identify the Target of Immune Attacks on Liver Cells in Metabolic Disorders - Weill Cornell Medicine Newsroom - August 22nd, 2022
- Why Is CAR T-Cell Therapy One of the Most Phenomenal Advances in Science? - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms - PR Newswire - August 22nd, 2022
- Cell Analysis Global Market Report 2022: Growing Focus on Personalized Medicine & Introduction of Advanced Technologies in Cell Analysis Presents... - August 22nd, 2022
- Stress can throw off circadian rhythms and lead to weight gain - Medical News Today - August 22nd, 2022
- Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimers Disease Patients, Findings Published in Science Translational Medicine - BioSpace - August 22nd, 2022
- Restoring cell and organ function after the heart stops - National Institutes of Health (.gov) - August 22nd, 2022
- Rolling the Dice: Gamble Pays Off For Cancer Patient in CAR T-Cell Clinical Trial - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Boosting neuron formation restores memory in mice with Alzheimer's disease - EurekAlert - August 22nd, 2022
- UTSW study finds p53 gene plays second role in suppressing genes tied to cancer - UT Southwestern - August 22nd, 2022
- GlyNAC supplementation reverses mitochondrial dysfunction, oxidative stress and aging hallmarks to boost strength and promote health in aging humans -... - August 22nd, 2022
- Multiple shots of the BCG vaccine protect type 1 diabetics from COVID-19 - EurekAlert - August 22nd, 2022
- Cell Regeneration Medicine Market Analysis by Type, Application, Growth, Demand, Status, and Forecast from 2022 to 2032 - Digital Journal - August 5th, 2022
- Higher Hydroxyurea Exposure Tied to Better Blood Parameters in US... - Sickle Cell Anemia News - August 5th, 2022
- Kiwis with multiple sclerosis patients thriving from overseas stem-cell treatment urge Government to approve it here - Newshub - July 27th, 2022
- MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug - PMLiVE - July 27th, 2022
- CAR T-Cell Therapy Turns 10 and Finally Earns the Word 'Cure' - Medscape - July 27th, 2022
- Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated... - July 27th, 2022
- CRISPR therapeutics can damage the genome - EurekAlert - July 27th, 2022
- To cell surface and beyond: Tracing subcellular glycoprotein transport using modified cholera toxin - EurekAlert - July 27th, 2022
- From Donor to Patient: Advancing the Future of Cell Therapies - Genetic Engineering & Biotechnology News - July 27th, 2022
- Five-Year Review of Biomedical Research Imaging Center, Center Director | Newsroom - UNC Health and UNC School of Medicine - July 27th, 2022
- Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer - Yale School of Medicine - July 11th, 2022
- Stem Cell Assays Market Report 2022-2027: Increasing Awareness About Therapeutic Potency of Stem Cells Driving Growth - ResearchAndMarkets.com -... - July 11th, 2022
- Sickle cell disease could be treated with common plant, study finds - The Telegraph - July 11th, 2022
- Unexpected link between most common cancer drivers may yield more effective drugs - University of Wisconsin-Madison - July 11th, 2022
- Scientists Discover Key to Hepatitis A Virus Replication, Show Drug Effectiveness | Newsroom - UNC Health and UNC School of Medicine - July 11th, 2022
- How Erectile Dysfunction Drugs Can Help Treat Cancer and Save Thousands of Lives - SciTechDaily - July 11th, 2022
- Pune: Dr Mohan Wani appointed as director of National Centre for Cell Science - The Indian Express - July 11th, 2022
- Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma - Gilead... - July 3rd, 2022
- Important Factors for Regulating the Body's Immune Response - Neuroscience News - July 3rd, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - July 3rd, 2022
- Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with... - July 3rd, 2022
- Growing scope of Genetic Medicine and Stem Cell Research - The Hindu - June 22nd, 2022
- When children with sickle cell grow up, they face a system not designed for them - 89.3 WFPL News Louisville - June 22nd, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 22nd, 2022
- Stem Cell Assays Market worth $4.5 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - June 22nd, 2022
- Bringing heart and humanity to hematology | News | Harvard TH Chan School of Public Health - HSPH News - June 22nd, 2022
- Belzutifan Improves Survival in Patients With RCC and VHL - Targeted Oncology - June 22nd, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 13th, 2022